SLC7A11 and neoplasm: In prostate cancer [96], liver cancer [97], and gastric cancer [98]; OSCC [99], melanoma [100], and bladder cancer [101]; and nasopharyngeal [102] and other cancers, SLC7A11 increases GSH levels, resists iron-related death, and promotes tumour cell metastasis respectively.